Fourth migraine drug arrives

By Megan Brodie 3 years ago | In Companies, Products
  • 3 years ago

14 May 2021 Lundbeck has submitted its CGRP inhibitor VYEPTI (eptinezumab) to the TGA for…

This is subscriber-only content. Please login to continue reading.